Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China.
Int J Mol Sci. 2024 Mar 29;25(7):3845. doi: 10.3390/ijms25073845.
Huntington's disease (HD) arises from the abnormal expansion of CAG repeats in the huntingtin gene (), resulting in the production of the mutant huntingtin protein (mHTT) with a polyglutamine stretch in its N-terminus. The pathogenic mechanisms underlying HD are complex and not yet fully elucidated. However, mHTT forms aggregates and accumulates abnormally in neuronal nuclei and processes, leading to disruptions in multiple cellular functions. Although there is currently no effective curative treatment for HD, significant progress has been made in developing various therapeutic strategies to treat HD. In addition to drugs targeting the neuronal toxicity of mHTT, gene therapy approaches that aim to reduce the expression of the mutant gene hold great promise for effective HD therapy. This review provides an overview of current HD treatments, discusses different therapeutic strategies, and aims to facilitate future therapeutic advancements in the field.
亨廷顿病(HD)是由亨廷顿基因()中 CAG 重复序列的异常扩增引起的,导致其 N 端出现多聚谷氨酰胺延伸的突变亨廷顿蛋白(mHTT)的产生。HD 的发病机制复杂,尚未完全阐明。然而,mHTT 形成聚集体并异常积聚在神经元核和突起中,导致多种细胞功能紊乱。虽然目前尚无有效的 HD 治疗方法,但在开发治疗 HD 的各种治疗策略方面已经取得了重大进展。除了针对 mHTT 神经元毒性的药物外,旨在降低突变基因表达的基因治疗方法为有效治疗 HD 提供了巨大的希望。本综述概述了目前的 HD 治疗方法,讨论了不同的治疗策略,并旨在促进该领域未来的治疗进展。